In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.
Bibliographical noteFunding Information:
L.T. has reported to the FDA numerous businesses selling unlicensed and unproven stem cell interventions. On a pro bono basis, L.T. filed an expert opinion report and rebuttal report supporting plaintiffs in a lawsuit filed against a business marketing purported stem cell interventions. L.T. was also deposed in this case and was examined and cross-examined in a court hearing. This work was also conducted on a pro bono basis. L.T. is a member of the International Society for Cell and Gene Therapy and a member of the International Society for Stem Cell Research.
© 2020 Elsevier Inc.